Medicine and Dentistry
Patient
100%
Psychosis
98%
Brain Imaging
90%
Dopamine Metabolism
68%
Fluorine-18
62%
Inpatient
60%
Positron Emission Tomography
60%
Receptor
45%
Clozapine
45%
N Methyl-D-Aspartate Receptor
45%
Bipolar Disorder
45%
Neuroimaging
45%
Meta-Analysis
45%
Glutamic Acid
45%
Methyldienolone
45%
Dextro Aspartic Acid
45%
Association
45%
Cost-Effectiveness Analysis
45%
Channel Modulator
45%
Cohort Analysis
45%
Autoanalysis
45%
Symptom
45%
Hippocampus
39%
Therapeutic Procedure
35%
Placebo
30%
Analysis
30%
Chemotherapeutic Agent
25%
Drug
25%
Striatum
24%
Disease
20%
Volunteer
20%
Ligand
16%
Brain
15%
Proton Nuclear Magnetic Resonance
15%
Test Retest Reliability
15%
Age
15%
Reproducibility
15%
Male
14%
Brain Region
12%
Health Care Cost
11%
Female
11%
Magnetic Resonance Imaging
11%
Ketamine
9%
Anterior Cingulate
9%
Cingulate Cortex
9%
Temporal Lobe
9%
Binding Site
9%
Thalamus
9%
Volume of Distribution
9%
Dopamine
7%
Neuroscience
Brain
60%
Psychosis
53%
Positron Emission Tomography
53%
Antipsychotic
45%
Eicosanoid Receptor
45%
Meta-Analysis
45%
Bipolar Disorder
45%
Methyldienolone
45%
Dextro Aspartic Acid
45%
Glutamic Acid
45%
Positron Emission Tomography
45%
Dementia Praecox
37%
Hippocampus
27%
Dopamine
22%
In Vivo
15%
Striatum
15%
White Matter
13%
Gray Matter
13%
Amygdala
13%
Magnetic Resonance Imaging
7%
Nuclear Magnetic Resonance Spectroscopy
7%
Disinhibition
7%
Ligand
7%
Thalamus
6%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
90%
Schizophrenia
63%
Clozapine
63%
Side Effect
45%
Cohort Study
45%
Negative Syndrome
25%
Pimavanserin
22%
Clinical Trial
22%
Serotonin Antagonist
22%
Dopamine Receptor Blocking Agent
22%
Roluperidone
22%
Tolerability
22%
Pharmacokinetics
18%
Positive Syndrome
14%
Treatment-Resistant Schizophrenia
11%
Receptor
11%
Dopamine Receptor Stimulating Agent
11%
Cariprazine
11%
Phase II Trials
11%
Antagonist
11%
Depression
11%
Brexpiprazole
11%
Lumateperone
11%
Relapse
11%
Partial Agonist
11%
Prevalence
9%
Symptom
5%